KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

AbCellera Biologics (ABCL) Operating Expenses: 2019-2024

Historic Operating Expenses for AbCellera Biologics (ABCL) over the last 6 years, with Dec 2024 value amounting to $343.6 million.

  • AbCellera Biologics' Operating Expenses rose 26.82% to $75.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was $275.2 million, marking a year-over-year increase of 2.35%. This contributed to the annual value of $343.6 million for FY2024, which is 24.84% up from last year.
  • As of FY2024, AbCellera Biologics' Operating Expenses stood at $343.6 million, which was up 24.84% from $275.2 million recorded in FY2023.
  • AbCellera Biologics' Operating Expenses' 5-year high stood at $343.6 million during FY2024, with a 5-year trough of $77.1 million in FY2020.
  • For the 3-year period, AbCellera Biologics' Operating Expenses averaged around $295.9 million, with its median value being $275.2 million (2023).
  • Data for AbCellera Biologics' Operating Expenses shows a peak YoY surged of 390.33% (in 2020) over the last 5 years.
  • AbCellera Biologics' Operating Expenses (Yearly) stood at $77.1 million in 2020, then spiked by 121.45% to $170.8 million in 2021, then spiked by 57.45% to $268.9 million in 2022, then increased by 2.35% to $275.2 million in 2023, then increased by 24.84% to $343.6 million in 2024.